Trial Profile
Pharmacokinetics Distribution of Raltegravir Using Radiolabeling in HIV-infected Patients by PET/MR: a Pilot Study.
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 09 Aug 2023 Planned End Date changed from 1 Jan 2022 to 1 Jan 2024.
- 09 Aug 2023 Planned primary completion date changed from 1 Nov 2021 to 1 Nov 2023.
- 10 Mar 2021 Planned End Date changed from 1 Jan 2021 to 1 Jan 2022.